| Title | Biosimulation Market worth $9.18 billion by 2029 |
|---|
| URL | https://www.marketsandmarkets.com/Market-Reports/biosimulation-market-838.html |
|---|
| Category | Fitness Health --> Health Articles |
|---|
| Meta Keywords | Biosimulation Market |
|---|
| Meta Description | The North America market is expected to be worth USD 3.21 billion by 2029, growing at a CAGR of 14.4% during the forecast period. |
|---|
| Owner | Healthcare101 |
|---|
| Description |
|---|
| The biosimulation market is projected to reach USD 9.18 billion by 2029 from USD 4.24 billion in 2024, at a CAGR of 16.7% from 2024 to 2029. The biosimulation market is experiencing significant growth driven by increasing R&D investments in the pharmaceutical and biotech industries. Biosimulation eases the drug discovery and development process by allowing predictive modeling of biological systems, which makes it easy to evaluate a drug’s safety and efficacy. This reduces drug discovery time and costs as it helps the user minimize the experimental work and optimize the clinical trial design. The AI-integrated biosimulation platforms like Orion by OpenEye, Cadence Molecular Sciences, and the BIOiSIM platform by VeriSIM Life offer more accuracy and efficiency, leading to better predictions in drug development. |
